Abstract
Systemic mastocytosis (SM) exemplifies the diagnostic and management challenges associated with rare diseases, which often involve prolonged time to diagnosis, limited access to clinical experts, and persistent symptom burden. Advanced practitioners (APs) are increasingly responsible for the care of patients with rare and classical hematologic disorders. The Advanced Practitioner Society for Hematology and Oncology (APSHO) convened a multidisciplinary, AP-led steering committee to evaluate the AP role in managing SM, develop an online toolkit, and design surveys to identify best practices, unmet needs, and practical strategies for improving care for patients living with indolent systemic mastocytosis (ISM). The toolkit emphasizes early symptom recognition, integration of validated patient-reported outcome measures, and incorporation of disease-specific tools into clinical workflows and electronic medical records (EMRs). The emergence of targeted therapies, such as avapritinib for both advanced and indolent SM, has further highlighted the need for AP education on novel disease mechanisms and treatment strategies. This project demonstrates a replicable model for developing educational and clinical resources to support APs in managing rare diseases and improving patient-centered care.
References
DeSantis, C. E., Kramer, J. L., & Jemal, A. (2017). The burden of rare cancers in the United States. CA: A Cancer Journal for Clinicians, 67(4), 261–272. https://doi.org/10.3322/caac.21400
Jennings, S. V., Slee, V. M., Zack, R. M., Verstovsek, S., George, T. I., Shi, H., Lee, P., & Castells, M. C. (2018). Patient perceptions in mast cell disorders. Immunology and Allergy Clinics of North America, 38(3), 505–525. https://doi.org/10.1016/j.iac.2018.04.006
Kurtin, S., Edwards, A., Nodzon, L., Bradley, T., May, M. B., Koniarczyk, H., Petraitis, C., Thompson, M., Tamassi, J., & Vogel, W. (2023). Advanced practitioners as agents of change: AP-led quality improvement initiatives to improve clinical outcomes in hematology and oncology. Journal of the Advanced Practitioner in Oncology, 14(Suppl 3), 35–42. https://doi.org/10.6004/jadpro.2023.14.7.13
Kurtin, S. (2017). Priming the pump: Preparing the advanced practitioner in oncology for scientific innovation. Journal of the Advanced Practitioner in Oncology, 8(5), 440–446. https://pmc.ncbi.nlm.nih.gov/articles/PMC6067918/
Panwar, P., Jones, J. M., Christian, J., Yui, J. C., & Naik, R. P. (2023). Under-representation of classical hematology training on hematology-oncology fellowship program websites in the United States. Blood Advances, 7(11), 2375–2377. https://doi.org/10.1182/bloodadvances.2022008162
Pulfer, S., Ziehfreund, S., Gebhard, J., Hindelang, B., Biedermann, T., Brockow, K., & Zink, A. (2021). Health-related quality of life and influencing factors in adults with nonadvanced mastocytosis—a cross-sectional study and qualitative approach. The Journal of Allergy and Clinical Immunology: In Practice, 9(8), 3166–3175.e2. https://doi.org/10.1016/j.jaip.2021.04.059
West, C. V., Butler, M. J., Kaur, S., Bowhay-Carnes, E., & Karnad, A. B. (2024). Classical hematology referrals at a National Cancer Institute-designated cancer center: Lessons learned. JCO Oncology Practice, 20(1), 131–135. https://doi.org/10.1200/op.23.00235
Zeiger, R. S., Tse, K. Y., Li, Q., Saparudin, M., Al-Salman, S. S., Puttock, E. J., Miller, K., Powell, D., Lampson, B., Sullivan, E., & Chen, W. (2025). Patient-reported burden of indolent systemic mastocytosis in a managed care organization. The Journal of Allergy and Clinical Immunology: In Practice, 13(1), 202–212.e7. https://doi.org/10.1016/j.jaip.2024.10.021
